Search

Cholesterol Efflux Modulation Compositions and Methods - US20260097053A1

USPTO published patent application US20260097053A1 for compositions and methods modulating cholesterol efflux via ABCA1 for treating atherosclerosis and related diseases. Invented by Kailash Gulshan, the application claims PIP2 compositions affecting ABCA1 levels and promoting reverse cholesterol transport (RCT) to reduce cholesterol and atherosclerosis. This is a patent application publication establishing a filing date, not a granted patent.

Novel Formulations and Vehicles for DAPTZ Compounds Including Methylene Blue

USPTO published patent application US20260097043A1 assigned to WisTa Laboratories Ltd., covering novel oral pharmaceutical formulations of diaminophenothiazine (DAPTZ) compounds such as methylene blue. The application discloses gastro-retentive platforms including film-coated solid tablets and buoyant self-orientating capsules with sustained-release coatings. The filing was submitted on September 20, 2023, under application number 19113777.

Implantable Device for Administering a Therapeutic Agent

USPTO published patent application US20260096984A1 filed by inventors Harsh Patel and Jeffrey Haley on October 3, 2025. The application covers an implantable device for delivering therapeutic agents, featuring a core polymer matrix with hydrophobic poly ortho ester (POE) polymer having a glass transition temperature between -20°C and 40°C. The device is designed for controlled therapeutic agent release in vivo.

Solanum Lycopersicum Plants Having Improved Tobamovirus Resistance

The USPTO published patent application US20260096533A1 granting protection for hybrid Solanum lycopersicum tomato plants containing the Rug-1 resistance gene that confers Tomato Brown Rugose Fruit Virus (ToBRFV) tolerance/resistance. The patent covers the plant, seeds, fruits, plant parts, and methods for identifying, selecting, and producing ToBRFV-resistant tomato plants using the specified genetic marker.

Understanding Responsibilities When Importing, Compounding and Supplying Unapproved Peptide Products

TGA has published a safety advisory warning of rising import, supply, compounding and advertising of unapproved peptide products in Australia. Products containing BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 are specifically identified as unapproved goods not evaluated for safety, quality, or effectiveness. The TGA states it is actively monitoring this issue from both safety and law enforcement perspectives and reminds affected parties of their obligations under the Therapeutic Goods Act 1989.

Teardrop Effervescent Tablet, Rapid Dissolution, Oral Drug Delivery

USPTO published patent application US20260096993A1 for a teardrop-shaped effervescent tablet designed for rapid dissolution oral drug delivery. The application (No. 18909065) was filed on October 8, 2024 and published April 9, 2026. Inventors Philip Mackenzie and Dan Aziz disclose a tablet with asymmetric geometry and cupped surfaces engineered to accelerate dissolution rates and improve bioavailability of active ingredients.

Solid Dispersions Having Stabilized Emulsion Particles Patent Application

USPTO published patent application US20260096994A1 for solid dispersion compositions containing active pharmaceutical ingredients and dispersion carriers. The application covers methods of dissolving API with carriers, combining with anti-solvent containing surfactant to form emulsions, and removing solvent to achieve predetermined particle size ranges. The application notably includes Compound (1) (zongertinib).

Biodegradable Microcapsules and Method for Their Preparation

USPTO published patent application US20260096991A1 for biodegradable microcapsules and methods for their preparation. The application relates to microcapsule compositions for drug delivery, classified under A61K. Filing date was September 7, 2023, with nine listed inventors.

Polymeric Delivery System Patent for Biologics

USPTO published patent application US20260096990A1 for a polymeric delivery system designed to deliver biologic therapeutics to cells. The invention covers polyplexes composed of charged polyesters and biologics, as well as self-assembled particles with block copolymers. The application was filed on December 12, 2025, by inventors Jeremy J. Harris, Scott Radzinski, Brian Ginn, Peter D. Gabriele, and Benjamin Roadarmel.

Pfizer PF-08653944 Safety Trial, Reduced Liver Function

Pfizer registered a Phase 1 clinical trial on ClinicalTrials.gov (NCT07519135) to evaluate the safety and pharmacokinetics of investigational drug PF-08653944 in participants with reduced liver function (hepatic impairment). The single-arm, open-label study aims to characterize how hepatic impairment affects the drug's safety profile and exposure. ClinicalTrials.gov serves as a public registry for clinical studies and does not constitute regulatory approval or review of the investigated product.